Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Tesamorelin Acetate
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Approves EGRIFTA SV PAS for Theratechnologies
Details : FDA has approved the Company’s PAS to the sBLA for Egrifta SV (tesamorelin acetate). Tesamorelin is the only treatment approved in the U.S. to reduce abdominal fat with HIV and lipodystrophy.
Product Name : Egrifta SV
Product Type : Hormone
Upfront Cash : Inapplicable
April 08, 2025
Lead Product(s) : Tesamorelin Acetate
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tesamorelin Acetate
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Theratechnologies’ EGRIFTA WR Approved for HIV-Related Lipodystrophy
Details : Egrifta WR (tesamorelin acetate) is a growth hormone releasing factor (GRF) analog used to reduce excessive abdominal fat in HIV patients who have developed lipodystrophy.
Product Name : Egrifta WR
Product Type : Hormone
Upfront Cash : Inapplicable
March 25, 2025
Lead Product(s) : Tesamorelin Acetate
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tesamorelin Acetate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Theratechnologies Receives March 2025 PDUFA Goal Date for Updated Tesamorelin
Details : Egrifta (tesamorelin) is a growth hormone releasing factor (GRF) analog used to reduce excessive abdominal fat in HIV patients who have developed lipodystrophy.
Product Name : Egrifta
Product Type : Hormone
Upfront Cash : Inapplicable
December 10, 2024
Lead Product(s) : Tesamorelin Acetate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tesamorelin Acetate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Theratechnologies Submits Updated Tesamorelin F8 Formulation sBLA for FDA Review
Details : Egrifta (tesamorelin) is a growth hormone releasing factor (GRF) analog used to reduce excessive abdominal fat in HIV patients who have developed lipodystrophy.
Product Name : Egrifta
Product Type : Hormone
Upfront Cash : Inapplicable
November 26, 2024
Lead Product(s) : Tesamorelin Acetate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tesamorelin Acetate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Theratechnologies Receives Complete Response Letter from FDA for F8 Tesamorelin sBLA
Details : Egrifta (tesamorelin) is a growth hormone releasing factor (GRF) analog used to reduce excessive abdominal fat in HIV patients who have developed lipodystrophy.
Product Name : Egrifta
Product Type : Hormone
Upfront Cash : Inapplicable
January 24, 2024
Lead Product(s) : Tesamorelin Acetate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tesamorelin Acetate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Theratechnologies Receives FDA Update on Tesamorelin F8 Biologics License Application
Details : Egrifta (tesamorelin) is a growth hormone releasing factor (GRF) analog used to reduce excessive abdominal fat in HIV patients who have developed lipodystrophy.
Product Name : Egrifta
Product Type : Hormone
Upfront Cash : Inapplicable
January 23, 2024
Lead Product(s) : Tesamorelin Acetate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tesamorelin Acetate
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Theratechnologies Submits Tesamorelin F8 Formulation sBLA for FDA Review
Details : EGRIFTA F8® (tesamorelin for injection) is approved in the United States and indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy.
Product Name : Tesamorelin F8
Product Type : Hormone
Upfront Cash : Inapplicable
September 25, 2023
Lead Product(s) : Tesamorelin Acetate
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tesamorelin Acetate
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : World Orphan Drug Alliance
Deal Size : Undisclosed
Deal Type : Agreement
Details : EGRIFTA SV® (tesamorelin for injection) is approved in the United States and indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy.
Product Name : Egrifta SV
Product Type : Hormone
Upfront Cash : Undisclosed
May 01, 2023
Lead Product(s) : Tesamorelin Acetate
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : World Orphan Drug Alliance
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Tesamorelin Acetate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Theratechnologies Receives January 2024 PDUFA Goal Date for Tesamorelin F8 Formulation sBLA
Details : EGRIFTA F8® (tesamorelin for injection) is approved in the United States and indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy.
Product Name : Egrifta MDV
Product Type : Hormone
Upfront Cash : Inapplicable
April 10, 2023
Lead Product(s) : Tesamorelin Acetate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tesamorelin Acetate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TH9507 (tesamorelin) stimulates growth hormone secretion (GHRH), and subsequently increases IGF-1 and IGFBP-3 levels. GHRH is indicated for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.
Product Name : Egrifta SV
Product Type : Hormone
Upfront Cash : Inapplicable
February 22, 2023
Lead Product(s) : Tesamorelin Acetate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable